Business Wire

Samsung Spotlights 2025 AV Line-Up with Samsung Vision AI: Next-Level Picture Quality and Smart Features Arrive in Europe

21.5.2025 14:13:00 CEST | Business Wire | Press Release

Share

Samsung Electronics Co., Ltd.'s latest 2025 AV line-up will become available from 26 May, and to celebrate the launch and the power of Samsung Vision AI, Samsung held its “Home of Vision” event, showcasing the power of AI in Movies, Gaming and Sports.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521585957/en/

Opening space of The Home of Vision, Powered by Samsung Vision AI

The Home of Vision event was an immersive adventure bringing to life Samsung’s vision to elevate TVs from screens to intelligent smart home companions that adapt to your needs, becoming the centrepiece of the home.

Jose Barreiro-Lopez, Vice President of TV and AV, Samsung Europe, commented: "Samsung has been the No. 1 TV globally for 19 years in a row. This year we are transforming our TVs into a true AI-powered companion, designed to be at the heart of every home.

Our event showcases the breadth of our TV line-up with the promise to elevate every home entertainment. Whether you are immersed in a cinematic film, cheering on your favourite sports team or enjoying a gaming session with your friends, our TVs are built to cater for every experience, and Samsung Vision AI elevates them to the next level.”

Unlock the Full Potential of Vision AI at Home

“The Home of Vision” event featured immersive, interactive zones designed to showcase consumers' favourite TV pastimes, Gaming, Movies and Sport, and how Samsung Vision AI was used to not only enhance the picture and sound of these experiences, but to create new ways to enjoy them.

A home cinema reimagines iconic film scenes with stunning clarity and depth, thanks to powerful AI Picture optimisation. Showcasing a diverse range of film genres, advanced AI technologies analyse the content and your surroundings to automatically adjust the picture to further enhance your experience.

The Film Experience also features AI Sound. By analysing your room’s acoustic properties, it dynamically adapts the sound to create rich, spatial audio that surrounds you. The audio performance of the new line-up has been upgraded, ideal for immersing yourself in a film or TV series. AI Sound works in combination with the latest Samsung Q-Series Soundbar line-up, which seamlessly integrates with the TVs via Q-Symphony, perfect for cinema-like quality at home.

The Sports Zone demonstrates how Samsung Vision AI intelligently adapts to your viewing set-up and the content you’re watching – offering a truly personalised experience for every sports fan.

Highlighting AI Motion Enhancer Pro, it sharpens low-resolution content, reduces blurring and ball distortion, allowing your TV to adapt for the sports you love watching. When watching fast-paced matches, such as football, AI Motion Enhancer Pro intelligently tracks the ball’s movement and enhances its resolution in real time – ensuring each moment appears crisp and clear, delivering a viewing experience that feels as immersive as being in the stadium.

For gamers, Samsung Vision AI can be a game-changer – an immersive e-sports inspired environment with QLED 4K QN90F displays, and dynamic lighting creates an engaging and atmospheric experience, showcasing features that respond to gameplay in real time.

AI Auto Game Mode automatically detects game titles and genres, fine-tuning settings to deliver a next-level experience – meaning gamers no longer need to manually adjust their settings. If you are a fan of RTS games then want to change over to an FPS, AI Auto Game Mode will adapt in real time, so you never miss a shot.

Powered by Samsung Vision AI, the latest Samsung TVs take viewing experience to the next level – with industry-leading Quantum Dot technology delivering vibrant, true-to-life visuals for an unforgettable viewing experience. Samsung’s Glare-Free technology, now introduced across select Neo QLED and OLED models, cuts reflections while preserving deep blacks and sharp images – even in bright rooms. A new anti-reflective material ensures stunning picture quality in any light.

Models such as the HW-Q990F and HW-Q930F offer a three-dimensional surround sound with support for Dolby Atmos and DTS:X, providing a superior audio experience.

The following models from the 2025 AV line-up will be available to purchase from 26th May 2025:

  • Neo QLED 8K TVs: starting at €3,499
  • Neo QLED 4K TVs: starting at €1,099
  • OLED TVs: starting at €1,549
  • QLED 4K TVs: starting at €749
  • Crystal UHD: starting at €469
  • The Frame: starting at €1,349 (from 43 inches)
  • Q-series Soundbars: starting at €549
  • B-series Soundbars: starting at €119

For more information about the latest TV line-up powered by Samsung Vision AI, please visit www.samsung.com.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, home appliances, network systems, and memory, system LSI, foundry and LED solutions, and delivering a seamless connected experience through its SmartThings ecosystem and open collaboration with partners. For the latest news, please visit the Samsung Newsroom at https://news.samsung.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250521585957/en/

Contacts

Amelia-Eve Warden / a.warden@samsung.com / +44 7442 827876

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye